Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I wonder when the first sales update will be, guessing around December.
BARHEMSYS launched in the US: https://acaciapharma.com/news/2020/08/barhemsys-amisulpride-injection-launched-and-commercially-available-in-the-us-for-the-treatment-and-prevention-of-postoperative-nausea-vomiting-ponv
The patent company for SNG ?
In the end the SP finished at roughly +10%.
That's in line with what I expected, given how "confidential" this share is, and seeing as this commercialisation agreement concerns a licenced products (so thinner profit margin).
I exited early in the morning on my PEA. Still have a few shares on my CTO which I'll continue to top up.
Naja, +16% today.
I hesitated heavily to sell my NCYT shares just to profit from this, but I was afraid a mega RNS could fall on the same day...
2nd FDA approval received:
http://acaciapharma.com/news/2020/07/acacia-pharma-announces-us-fda-approval-of-byfavo-remimazolam-for-injection-for-the-induction-and-maintenance-of-procedural-sedation
Time for a decent re-rate.
So, the upcoming approval could be announced either tomorrow oder nächste Montag.
They've already gotten a commercialisation approval in the USA for one product, and a second one could come in July.